Compare UMC & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | DGX |
|---|---|---|
| Founded | 1980 | 1967 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 20.5B |
| IPO Year | 2000 | 1996 |
| Metric | UMC | DGX |
|---|---|---|
| Price | $8.12 | $176.21 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $196.69 |
| AVG Volume (30 Days) | ★ 9.2M | 1.1M |
| Earning Date | 01-20-2026 | 01-29-2026 |
| Dividend Yield | ★ 4.59% | 1.82% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 0.10 | ★ 8.51 |
| Revenue | $7,746,022,974.00 | ★ $10,850,000,000.00 |
| Revenue This Year | $3.20 | $12.37 |
| Revenue Next Year | $6.45 | $3.52 |
| P/E Ratio | ★ $15.32 | $20.68 |
| Revenue Growth | 4.08 | ★ 13.74 |
| 52 Week Low | $5.61 | $148.70 |
| 52 Week High | $8.33 | $197.55 |
| Indicator | UMC | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 36.92 |
| Support Level | $7.78 | $178.61 |
| Resistance Level | $8.16 | $179.80 |
| Average True Range (ATR) | 0.14 | 2.77 |
| MACD | 0.02 | -0.87 |
| Stochastic Oscillator | 91.13 | 15.42 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.